NIKKEI 225
38,244.30 -29.75 (-0.08%) HANG SENG
18,155.28 +392.25 (+2.21%) CRUDE OIL
79.56 +0.56 (+0.71%) GOLD FUTURES
2,328.70 +17.70 (+0.77%) DOW
37,903.29 +87.37 (+0.23%) Bitcoin GBP
45,783.62 -2,232.92 (-4.65%)
GSK Nov 2024 48.000 call
| Previous close | 0.7000 |
| Open | 0.6500 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 48.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.6500 - 0.7000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
BenzingaGSK Sees Strong Demand For Vaccines and Asthma Drugs, Raises Annual Outlook
Wednesday, GSK Plc (NYSE:GSK) reported first-quarter sales of $9.33 billion (7.4 billion Sterling Pounds), up 10% Y/Y and 13% excluding COVID. Vaccines’ sales increased 16% at constant currency to 2.28 billion Pounds, reflecting U.S. demand for Arexvy and strong market growth for Shingrix in International and European markets. Shingrix sales reached 945 million Pounds, up 18% at constant currency, with Arexvy sales of 182 million Pounds. Specialty Medicine sales increased 17% to 2.5 billion poun
PA Media: MoneyGSK raises profit guidance as vaccine demand grows
Emma Walmsley, chief executive officer of the pharmaceutical firm hailed a ‘strong start to 2024’.
ZacksGSK (GSK) Q1 Earnings and Revenues Surpass Estimates
Glaxo (GSK) delivered earnings and revenue surprises of 15.96% and 3.99%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
